Kejadian Demam Neutropenia pada Pasien Kanker Payudara setelah Menerima Regimen Kemoterapi TAC-G-CSF dan FAC di RSUP Dr. Hasan Sadikin Bandung - Nusaibah A. Hima; Retnosari Andrajati; Maksum Radji (Universitas Padjadjaran, 2021)
Demam neutropenia merupakan efek samping yang sering terjadi setelah kemoterapi. Demam neutropenia dapat menyebabkan penundaan dosis kemoterapi sehingga dapat mengurangi efektivitas terapi. Kejadian demam neutropenia setelah kemoterapi dapat dicegah dengan pemberian Granulocyte-colony Stimulating Factor (G-CSF). Regimen kemoterapi yang digunakan dapat memengaruhi kejadian demam neutropenia. Selain itu, usia, stadium kanker, riwayat kemoterapi dan kadar hemoglobin sebelum kemoterapi merupakan faktor risiko demam neutropenia setelah kemoterapi. Penelitian ini bertujuan untuk mengetahui perbandingan kejadian demam neutropenia regimen Dosetaksel, Doksorubisin, Siklofosfamid (TAC) dengan profilaksis primer G-CSF dan regimen Fluorourasil, Doksorubisin, Siklofosfamid (FAC) pada pasien kanker payudara di RSUP Dr. Hasan Sadikin Bandung periode Januari 2017–Juni 2019. Desain penelitian adalah cross sectional uji dua populasi. Jumlah sampel sebanyak 61 regimen TAC-G-CSF dan 102 regimen FAC. Kejadian demam neutropenia dianalisis menggunakan Chi-Square, Kruskal Wallis dan regresi logistik. Hasil penelitian menunjukkan kejadian demam neutropenia setelah kemoterapi pada regimen TAC dengan profilaksis primer G-CSF lebih tinggi dibanding pada regimen FAC. Usia, stadium kemoterapi, riwayat kemoterapi dan kadar hemoglobin sebelum kemoterapi secara statistik tidak signifikan memengaruhi kejadian demam neutropenia setelah kemoterapi.Kata kunci: Demam neutropenia, FAC, granulocyte-colony stimulating factor (G-CSF), regimen kemoterapi, TAC The Incidence of Febrile Neutropenia in Patients with Breast Cancer after Receiving TAC-G-CSF and FAC Chemotherapy Regimen at Dr. Hasan Sadikin Hospital Bandung AbstractFebrile neutropenia is a common side effect of chemotherapy, and it reduces the effectiveness of therapy through the delay in chemo doses. Granulocyte-colony Stimulating Factor (G-CSF) is administered to prevent its incidence. The chemotherapy regimen affects the incidence of febrile neutropenia. Risk factors for febrile neutropenia include; age, stage of cancer, history of chemotherapy and pre-chemotherapy hemoglobin level. The purpose of this study was to compare the incidence of febrile neutropenia between Docetaxel, Doxorubicin, Cyclophosphamide (TAC) regimen with G-CSF primary prophylaxis and Fluorouracil, Doxorubicin, Cyclophosphamide (FAC) regimen in patients with breast cancer at Dr. Hasan Sadikin Hospital Bandung at the period of January 2017–June 2019. The cross-sectional study design of two populations was used. The sample consisted of 61 TAC and 102 FAC regimens. The Chi-Square, Kruskal Wallis, and logistic regression were used to analyze the incidence of febrile neutropenia. The results showed that the incidence of post-chemotherapy febrile neutropenia in TAC regimen with G-CSF primary prophylaxis was higher compared with FAC regimen. Furthermore, the risk factors had no statistical influence on the incidence of febrile neutropenia. Keywords: Chemotherapy regimen, FAC, febrile neutropenia, granulocyte-colony stimulating factor (G-CSF), TAC